Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LPD008
MIFTS: 62

Lipid Metabolism Disorder

Categories: Immune diseases, Liver diseases, Metabolic diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Lipid Metabolism Disorder

About this section

MalaCards integrated aliases for Lipid Metabolism Disorder:

Name: Lipid Metabolism Disorder 12 15
Dyslipidemia 12 54 15
Disorder of Fatty Acid Metabolism 29 71
Abnormality of Lipid Metabolism 29 6
Lipid Metabolism Disorders 42 71
Lipid Metabolism, Inborn Errors 43
Fatty Acid Metabolism Disorder 12
Disorder of Lipid Metabolism 58
Dyslipidemias 71

Classifications:

MalaCards categories:
Global: Metabolic diseases Rare diseases
Anatomical: Neuronal diseases Immune diseases Liver diseases
See all MalaCards categories (disease lists)
ICD10: 32
Orphanet: 58  
Inborn errors of metabolism


External Ids:

Disease Ontology 12 DOID:3146
MeSH 43 D008052
ICD10 32 E71.3
UMLS via Orphanet 72 C0154251
Orphanet 58 ORPHA309005
UMLS 71 C0023772 C0154251 C0242339 more
Sources

Summaries for Lipid Metabolism Disorder

About this section
MedlinePlus : 42 Metabolism is the process your body uses to make energy from the food you eat. Food is made up of proteins, carbohydrates, and fats. Chemicals in your digestive system (enzymes) break the food parts down into sugars and acids, your body's fuel. Your body can use this fuel right away, or it can store the energy in your body tissues. If you have a metabolic disorder, something goes wrong with this process. Lipid metabolism disorders, such as Gaucher disease and Tay-Sachs disease, involve lipids. Lipids are fats or fat-like substances. They include oils, fatty acids, waxes, and cholesterol. If you have one of these disorders, you may not have enough enzymes to break down lipids. Or the enzymes may not work properly and your body can't convert the fats into energy. They cause a harmful amount of lipids to build up in your body. Over time, that can damage your cells and tissues, especially in the brain, peripheral nervous system, liver, spleen, and bone marrow. Many of these disorders can be very serious, or sometimes even fatal. These disorders are inherited. Newborn babies get screened for some of them, using blood tests. If there is a family history of one of these disorders, parents can get genetic testing to see whether they carry the gene. Other genetic tests can tell whether the fetus has the disorder or carries the gene for the disorder. Enzyme replacement therapies can help with a few of these disorders. For others, there is no treatment. Medicines, blood transfusions, and other procedures may help with complications.

MalaCards based summary : Lipid Metabolism Disorder, also known as dyslipidemia, is related to hyperlipoproteinemia, type iii and hypolipoproteinemia. An important gene associated with Lipid Metabolism Disorder is FADS1 (Fatty Acid Desaturase 1), and among its related pathways/superpathways are Metabolism and Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha). The drugs Nifedipine and Mirabegron have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and kidney, and related phenotypes are Decreased free cholesterol and Decreased LDL uptake

Disease Ontology : 12 An inherited metabolic disorder that involves the creation and degradation of lipids.

Wikipedia : 74 Lipid metabolism is the synthesis and degradation of lipids in cells, involving the breakdown or storage... more...

Sources

Related Diseases for Lipid Metabolism Disorder

About this section

Diseases related to Lipid Metabolism Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 660)
# Related Disease Score Top Affiliating Genes
1 hyperlipoproteinemia, type iii 33.3 LPL LPA LIPC CETP APOE APOB
2 hypolipoproteinemia 33.1 LPL LPA COG2 CETP APOE APOC3
3 abdominal obesity-metabolic syndrome 1 33.0 SERPINE1 RETN PPARG PPARA LPL LEP
4 lipodystrophy, familial partial, type 2 32.8 PPARG PPARA LEP INS ADIPOQ
5 sitosterolemia 32.7 HMGCR APOB APOA1
6 prediabetes syndrome 32.6 PPARG PPARA LEP INS CRP COG2
7 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 31.8 LEP INS ADIPOQ
8 lipoprotein quantitative trait locus 31.7 SERPINE1 LPA HMGCR CRP COG2 APOB
9 chronic kidney disease 31.5 SERPINE1 RETN LPL LPA LIPC LEP
10 non-alcoholic steatohepatitis 31.5 SERPINE1 PPARG PPARA INS APOE ADIPOQ
11 arteries, anomalies of 31.5 SERPINE1 PPARG LPA LEP INS CRP
12 fatty liver disease 31.3 RETN PPARG PPARA LEP INS CRP
13 hyperlipidemia, familial combined, 3 31.3 PPARA LPL LIPC INS COG2 CETP
14 gestational diabetes 31.3 RETN PPARG LEP INS CRP ADIPOQ
15 peripheral vascular disease 31.3 SERPINE1 LPA INS HMGCR CRP COG2
16 pre-eclampsia 31.3 SERPINE1 LEP INS CRP ADIPOQ
17 sleep apnea 31.3 SERPINE1 RETN PPARG LEP INS CRP
18 peripheral artery disease 31.3 RETN CRP APOE APOB APOA1
19 cerebrovascular disease 31.3 SERPINE1 RETN LPL LPA LEP INS
20 hypoalphalipoproteinemia 31.2 LIPC APOA1
21 hyperandrogenism 31.2 PPARG INS ADIPOQ
22 vascular disease 31.2 SERPINE1 RETN PPARG LPL LPA LIPC
23 hyperthyroidism 31.2 RETN LEP INS CRP
24 acute myocardial infarction 31.1 SERPINE1 LPA HMGCR CRP APOB APOA1
25 fatty liver disease, nonalcoholic 1 31.1 RETN PPARA LEP INS ADIPOQ
26 anovulation 31.1 LEP INS CRP
27 stroke, ischemic 31.0 SERPINE1 LPA HMGCR CRP COG2 APOE
28 eye disease 31.0 PPARA INS HMGCR CRP APOA1
29 leptin deficiency or dysfunction 31.0 RETN PPARG PPARA LPL LEP INS
30 liver disease 31.0 RETN PPARA LEP INS ADIPOQ
31 homocysteinemia 31.0 SERPINE1 LPA CRP APOE
32 proteasome-associated autoinflammatory syndrome 1 31.0 PPARG PPARA CRP ADIPOQ
33 hyperlipoproteinemia, type i 31.0 LPL LIPC APOE APOC3 APOB APOA5
34 aortic aneurysm, familial abdominal, 1 31.0 CRP CETP APOE
35 hyperinsulinism 31.0 SERPINE1 RETN PPARG PPARA LPL LEP
36 diabetes mellitus, noninsulin-dependent 30.9 SERPINE1 RETN PPARG PPARA LPL LPA
37 acquired immunodeficiency syndrome 30.9 CRP APOE APOB APOA1
38 pancreatitis 30.9 LPL INS CRP APOA5
39 amyloidosis 30.9 LPA INS CRP APOE APOA1
40 heart disease 30.9 SERPINE1 PPARG PPARA LPL LPA LEP
41 diabetes mellitus, type i 30.9 RETN PPARG LPA LEP INS CRP
42 sleep disorder 30.9 LEP INS CRP APOE ADIPOQ
43 bone resorption disease 30.9 PPARG LEP INS CRP
44 polycystic ovary syndrome 30.9 RETN PPARG LEP INS CRP ADIPOQ
45 carotid stenosis 30.9 LPA CRP APOE ADIPOQ
46 alzheimer disease 30.9 PPARG PPARA LPL INS HMGCR CETP
47 arteriosclerosis 30.8 SERPINE1 PPARG PPARA LPL LPA INS
48 severe pre-eclampsia 30.8 SERPINE1 LEP ADIPOQ
49 amyloidosis aa 30.8 LPA CRP APOA1
50 acanthosis nigricans 30.8 PPARG LEP INS ADIPOQ

Comorbidity relations with Lipid Metabolism Disorder via Phenotypic Disease Network (PDN):


Hypertension, Essential Intermediate Coronary Syndrome

Graphical network of the top 20 diseases related to Lipid Metabolism Disorder:



Diseases related to Lipid Metabolism Disorder
Sources

Symptoms & Phenotypes for Lipid Metabolism Disorder

About this section

GenomeRNAi Phenotypes related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 8.65 LIPC
2 Decreased LDL uptake GR00340-A-1 8.32 LPL

MGI Mouse Phenotypes related to Lipid Metabolism Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.25 ADIPOQ APOA1 APOA5 APOB APOE COG2
2 cardiovascular system MP:0005385 10.11 ADIPOQ APOA1 APOB APOE CRP INS
3 adipose tissue MP:0005375 10.06 ADIPOQ APOE INS LEP LPL PPARA
4 immune system MP:0005387 10 ADIPOQ APOB APOE CRP FADS1 INS
5 integument MP:0010771 9.81 ADIPOQ APOA1 APOE INS LEP LPL
6 liver/biliary system MP:0005370 9.73 ADIPOQ APOA1 APOB APOE HMGCR INS
7 muscle MP:0005369 9.23 ADIPOQ APOB APOE INS LEP LPL
Sources

Drugs & Therapeutics for Lipid Metabolism Disorder

About this section

Drugs for Lipid Metabolism Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 624)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nifedipine Approved Phase 4 21829-25-4 4485
2
Mirabegron Approved Phase 4 223673-61-8 9865528
3
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
4
Metformin Approved Phase 4 657-24-9 14219 4091
5
Nevirapine Approved Phase 4 129618-40-2 4463
6
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
7
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
8
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
9
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
10
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
11
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
12
Polyestradiol phosphate Approved Phase 4 28014-46-2
13
Bilberry Approved, Experimental Phase 4
14
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
15
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
16
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
17
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
18
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
19
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
20 Orange Approved Phase 4
21
leucovorin Approved Phase 4 58-05-9 6006 143
22
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
23
tannic acid Approved Phase 4 1401-55-4
24
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
25
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
26
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
27
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
28
Ciprofibrate Approved, Investigational Phase 4 52214-84-3 2763
29
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
30
Calcium polycarbophil Approved Phase 4 126040-58-2
31
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
32
Bexarotene Approved, Investigational Phase 4 153559-49-0 82146
33
Infliximab Approved Phase 4 170277-31-3
34
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
35
Glyburide Approved Phase 4 10238-21-8 3488
36
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
37
Febuxostat Approved Phase 4 144060-53-7 134018
38
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
39
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
40
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
41
Insulin glargine Approved Phase 4 160337-95-1
42
Alendronate Approved Phase 4 66376-36-1, 121268-17-5 2088
43
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
44
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
45
Dulaglutide Approved, Investigational Phase 4 923950-08-7
46
Insulin aspart Approved Phase 4 116094-23-6 16132418
47
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
48
Insulin detemir Approved Phase 4 169148-63-4 5311023
49
Histamine Approved, Investigational Phase 4 51-45-6 774
50
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4

Interventional clinical trials:

(show top 50) (show all 1971)
# Name Status NCT ID Phase Drugs
1 Study on the Efficacy aNd Safety of Jinlida Granules in Patients With Inadequately cOntrolled tYpe-2 Diabetes and dysLIpidemia Under liFe Style Intervention (ENJOY LIFE Study) Unknown status NCT02035644 Phase 4 Jinlida granules;placebo granules
2 An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate Simvastatin 20 mg Plus Omacor 4g Compared to Simvastatin 20 mg Plus Placebo in Subjects With Mixed Dyslipidemia Unknown status NCT00678743 Phase 4 Omacor + simvastatin
3 Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia Unknown status NCT01010516 Phase 4 High-dose rosuvastatin;Statin plus fenofibrate;Statin plus niacin ER/laropiprant
4 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
5 Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)-A Randomized Controlled Trial Unknown status NCT00712049 Phase 4 simvastatin;Nicotinic Acid
6 An Open-label, Randomized, Multi-centre, Phase IVb, Parallel Study Group to Compare the Efficacy and Safety of 5 mg and 10 mg Rosuvastatin Unknown status NCT01613729 Phase 4 Rosuvastatin 5 mg;Rosuvastatin 10 mg
7 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
8 The Metabolic and Anti-Inflammatory Effects of Combined Ezetimibe and Simvastin Therapy, as Compared to Simvastatin Alone, in Patients With Chronic Proteinuric Nephropathy Unknown status NCT00861731 Phase 4 simvastatin;EZE/simvastatin;EZE/simvastatin
9 What is the Effects of Incretin on the Blood Pressure and Lipid in Overweight or Obese Diabetes Patients With Masked Hypertension: Liraglutide Plus Mitiglinide Comparing Metformin Plus Mitiglinide or Mitiglinide Alone（BLOOD STUDY） Unknown status NCT02503943 Phase 4 "Liraglutide" and "Mitiglinide";"Metformin" and "Mitiglinide";"Mitiglinide"
10 Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation Unknown status NCT01162902 Phase 4 Diltiazem treated group;Bisoprolol treated group;Candesartan treated group
11 The Effect of Exenatide on Brown Adipose Tissue Activity and Energy Expenditure in Healthy Young Men Unknown status NCT03002675 Phase 4 Bydureon
12 The Efficacy and Safety of Niacin on Hyperphosphatemia in End Stage Renal Disease Patients Undergoing Haemodialysis Unknown status NCT03163576 Phase 4 Niacin;Phosphate Binder
13 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
14 Effectiveness and Safety of Low-dose vs. High-dose Rosuvastatin on Long-term Cardiovascular Events in Korean Patients After Percutaneous Coronary Intervention: 30-month, Prospective, Single-center, Randomized Trial Unknown status NCT02859480 Phase 4 Rosuvastatin 5mg;Rosuvastatin 20mg
15 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4 Vitamin D3
16 What is the Effects of Prokinetic Drug on the Blood Glucose in Type 2 Diabetes Patients: Mosapride Comparing Placebo Unknown status NCT02606617 Phase 4 Mosapride;Placebo
17 A Randomized Controlled Study of Nifecardia SRFC (Nifedipine) and Adalat OROS (Nifedipine) in the Treatment of Patients With Essential Hypertension Unknown status NCT00173667 Phase 4 Nifedipine 30 mg GITS
18 Effects of Dapagliflozin on Hyperlipidemia, Glycemic Control and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study) Unknown status NCT02577159 Phase 4 Dapagliflozin
19 A Multicenter, Open Labeled, Cross-Over Designed Prospective Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis Unknown status NCT00433823 Phase 4 Atorvastatin, Ezetimibe
20 A Randomized Controlled Trial Comparing Usual Care With a Multifactorial Intensified Intervention on Cardiovascular Risk Factors in Subjects With Arterial Peripheral Disease With and Without Diabetes. The Taulí Intervention Program (TIP). Unknown status NCT00144937 Phase 4 Stepwise therapy for dyslipidemia, hypertension and diabetes
21 Effects of Growth Hormone on Body Fat Distribution, Insulin Action and Cardiovascular Risk Factors in Middle-Aged Men With Metabolic Syndrome Unknown status NCT00307411 Phase 4 Growth hormone
22 A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy Unknown status NCT02314533 Phase 4 fenofibrate
23 The Effects of Pravastatin and Rosuvastatin on the Tissue Characteristics and Morphology of Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
24 Effect of Pitavastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease Unknown status NCT02863185 Phase 4 Pitavastatin;Atorvastatin
25 Safety and Efficacy of Angiotensin Receptor Blocker, Fimasartan, on Patients With Aortic Stenosis Unknown status NCT01589380 Phase 4 Fimasartan;Placebo
26 The Effect of Mirabegron on Brown Adipose Tissue in Healthy Young White Caucasian and South Asian Men Unknown status NCT03012113 Phase 4 Mirabegron;Placebo Oral Capsule
27 The Low HDL On Six Weeks Statin Therapy (LOW) Study Unknown status NCT00238004 Phase 4 Nicotinic acid
28 The ACT-OUT Trial: ACTivity OUTcomes Based on the Consumption of a High Carbohydrate or High Fat Diet in Patients With Metabolic Syndrome Unknown status NCT01357382 Phase 4
29 Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia Completed NCT00651963 Phase 4 ezetimibe
30 A 12-week, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel-group Study to Assess the Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily Compared to Fluvastatin Sodium Immediate Release Capsules 40 mg Twice Daily (BID) in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia at Moderate or High Cardiovascular Risk Who Did Not Achieve Their Lipid Goals When Treated With Fluvastatin Sodium Immediate Release Capsules 40 mg QD Completed NCT01551173 Phase 4 Fluvastatin sodium
31 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk Completed NCT02957682 Phase 4 Praluent (Alirocumab);Placebo
32 The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM) Completed NCT01527318 Phase 4 Fibrate treatment
33 Effect of PPAR-Delta Agonist on Lipoprotein Kinetics in Metabolic Syndrome Completed NCT00841217 Phase 4 GW501516;placebo pill
34 Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study Completed NCT00701727 Phase 4 ezetimibe;Placebo
35 Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers Completed NCT00171262 Phase 4 Fluvastatin
36 A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects With Dyslipidemia, Followed by a 40-Week Safety Extension Study Completed NCT01301066 Phase 4 Pitavastatin;Pravastatin
37 Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients Completed NCT00654628 Phase 4 ezetimibe (+) simvastatin
38 A RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, PARALLEL GROUP STUDY OF PITAVASTATIN 4 MG VS. PRAVASTATIN 40 MG IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA Completed NCT01256476 Phase 4 pitavastatin;pravastatin
39 A Multi-center, Randomized, Double-blinded Equivalence Clinical Trial to Evaluate Efficacy and Safety of LipiLou 20 mg Versus Lipitor 20 mg in Hypercholesterolemic Patients With Higher Risk Cardiovascular Disease in Korea Completed NCT01029522 Phase 4 Atorvastatin (Lipilou);Atorvastatin (Lipitor)
40 Assessment of the Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia : A Multicenter, Prospective, Open-Label, Randomized, Trial Completed NCT01285544 Phase 4 Atorvastatin (Lipinon);Atorvastatin (Lipitor)
41 Efficacy and Tolerability of Fluvastatin in Adults With Dislipidemia With History of Muscle Problems Due to Other Previous Statin Intake Completed NCT00125125 Phase 4 Fluvastatin
42 A Multicenter, Pragmatic Randomized, Double-blind, Placebo-controlled Trial of Xuezhikang Capsule for Treating Dyslipidemia: a Postmarketing Study Completed NCT02057302 Phase 4 Xuezhikang capsule
43 Efavirenz to Nevirapine Switch in HIV-1 Infected Patients With Severe Dyslipidemia: A Randomized Controlled Study Completed NCT00405171 Phase 4 Nevirapine
44 A 16-week Multicenter, 2-period Study to Investigate the Effect of the Combination of Fluvastatin ER 80mg and Fenofibrate 200mg on HDL-C in Comparison to the Combination of Simvastatin 20mg and Ezetimibe 10mg in Patients With Metabolic Syndrome Completed NCT00385658 Phase 4 Fluvastatin extended release, fenofibrate;Fixed combination simvastatin/ezetimibe
45 Metformin for Treatment of Antipsychotic-induced Dyslipidemia: a Randomized, Double-blind Study Completed NCT01778244 Phase 4 metformin
46 An Outcome Research on the Impact of a Disease Management Program (COACH) on the Attainment of Better Cardiovascular Risk Control in Dyslipidemic Patients at Primary Care Centers (DISSEMINATE). Completed NCT00708370 Phase 4
47 Efficacy and Safety of Fluvastatin 80 mg or Valsartan 160 mg and Their Combination in Dyslipidemic Patients With Arterial Hypertension and Endothelial Dysfunction Completed NCT00171327 Phase 4 valsartan, fluvastatin
48 Neointimal Coverage After Implantation of Biolimus Eluting Stent With Biodegradable Polymer: Optical Coherence Tomographic Assessment According to the Treatment of Dyslipidemia and Hypertension and the Types of Implanted Drug-eluting Stents Completed NCT01502904 Phase 4 pravastatin 20mg/day after DES implantation;pitavastatin 2mg/day after DES implantation;Non-ARB /day after DES implantation;Eposartan 600mg/day after DES implantation
49 A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia Completed NCT01239004 Phase 4 Placebo;Colesevelam
50 An 8-Week Randomized, Double-Blind, Placebo-Controlled Trial Examining The Efficacy And Safety Of Caduet® In Simultaneously Achieving Blood Pressure And Lipid Goals In An Untreated Hypertensive And Dyslipidemic Subject Population. (CUSP - Caduet in Untreated Subject Population) Completed NCT00332761 Phase 4 Caduet

Search NIH Clinical Center for Lipid Metabolism Disorder

Cochrane evidence based reviews: lipid metabolism, inborn errors

Sources

Genetic Tests for Lipid Metabolism Disorder

About this section

Genetic tests related to Lipid Metabolism Disorder:

# Genetic test Affiliating Genes
1 Disorder of Fatty Acid Metabolism 29
2 Abnormality of Lipid Metabolism 29
Sources

Anatomical Context for Lipid Metabolism Disorder

About this section

MalaCards organs/tissues related to Lipid Metabolism Disorder:

40
Liver, Heart, Kidney, Endothelial, Ovary, Testes, Thyroid
Sources

Publications for Lipid Metabolism Disorder

About this section

Articles related to Lipid Metabolism Disorder:

(show top 50) (show all 26847)
# Title Authors PMID Year
1
Fenofibrate monotherapy-induced rhabdomyolysis in a patient with post-pancreatitis diabetes mellitus: A rare case report and a review of the literature. 61 42
32481339 2020
2
Case Report: The First Case of COVID-19 in Bhutan. 42
32314685 2020
3
Bempedoic acid (Nexletol) for lowering LDL-cholesterol. 42
32324179 2020
4
Targeting dyslipidemia in the metabolic syndrome: an update. 61 54
19485929 2010
5
Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. 54 61
20388526 2010
6
Association of low testosterone with metabolic syndrome and its components in middle-aged Japanese men. 54 61
20339372 2010
7
Insulin resistance is associated with C-reactive protein independent of abdominal obesity in nondiabetic Taiwanese. 61 54
20004425 2010
8
Ala54Thr polymorphism of fatty acid-binding protein 2 gene and fasting blood lipids: a meta-analysis. 54 61
20047744 2010
9
A novel germline mutation in peroxisome proliferator-activated receptor gamma gene associated with large intestine polyp formation and dyslipidemia. 61 54
20123124 2010
10
Insulin resistance, dyslipidemia, and metabolic syndrome in women with polycystic ovary syndrome. 54 61
20199774 2010
11
Is there a link between inflammation and abnormal lipoprotein profile in Sjögren's syndrome? 61 54
20378384 2010
12
Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. 61 54
19922962 2010
13
Fenofibrate antagonizes Chk2 activation by inducing Wip1 expression: implications for cell proliferation and tumorigenesis. 54 61
20226795 2010
14
The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. 61 54
20005515 2010
15
Peroxisome proliferator-activated receptor-delta genotype influences metabolic phenotype and may influence lipid response to statin therapy in humans: a genetics of diabetes audit and research Tayside study. 61 54
20200337 2010
16
Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model. 54 61
19965597 2010
17
Concordance of two multiple analytical approaches demonstrate that interaction between BMI and ADIPOQ haplotypes is a determinant of LDL cholesterol in a general French population. 61 54
20186155 2010
18
[Statins in the management of acute coronary syndrome]. 54 61
20387563 2010
19
Cardiovascular and metabolic risk profile and acylation-stimulating protein levels in children with Prader-Willi syndrome and effects of growth hormone treatment. 61 54
20173020 2010
20
Hormone and pharmaceutical regulation of ASP production in 3T3-L1 adipocytes. 61 54
20069551 2010
21
Type 2 diabetes mellitus is characterized by reduced postprandial adiponectin response: a possible link with diabetic postprandial dyslipidemia. 54 61
19922965 2010
22
Interrelationships of Factor VII activity and plasma leptin with insulin resistance in coronary heart disease. 61 54
19781705 2010
23
Bone mineral density and atherosclerosis: the Multi-Ethnic Study of Atherosclerosis, Abdominal Aortic Calcium Study. 61 54
19819456 2010
24
Pharmacologic inhibition of phospholipid transfer protein activity reduces apolipoprotein-B secretion from hepatocytes. 61 54
19933370 2010
25
Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans. 54 61
20016053 2010
26
[Effects of PPARgamma agonist on dyslipidemia and atherosclerosis]. 61 54
20158099 2010
27
Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis. 54 61
19910639 2010
28
Bezafibrate induces myotoxicity in human rhabdomyosarcoma cells via peroxisome proliferator-activated receptor alpha signaling. 54 61
19683050 2010
29
Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. 61 54
20104931 2010
30
[Prevalence of cardiovascular disease in uraemia and relevance of cardiovascular risk factors]. 54 61
20514101 2010
31
Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. 61 54
19699495 2010
32
Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia. 61 54
20425272 2010
33
The common biological basis for common complex diseases: evidence from lipoprotein lipase gene. 61 54
19639021 2010
34
[A case-control study on risk factors of type 2 diabetes mellitus related chronic complications in Baoding city]. 61 54
20193318 2009
35
Decrease in FASN expression in adipose tissue of hypertensive individuals. 54 61
19851294 2009
36
Effects of weight loss on lipid transfer proteins in morbidly obese women. 61 54
19789902 2009
37
Expression of human apoAII in transgenic rabbits leads to dyslipidemia: a new model for combined hyperlipidemia. 54 61
19778946 2009
38
Decreased PPAR gamma expression compromises perigonadal-specific fat deposition and insulin sensitivity. 54 61
19749155 2009
39
Serum retinol-binding protein 4 correlates with obesity, insulin resistance, and dyslipidemia in HIV-infected subjects receiving highly active antiretroviral therapy. 61 54
19501863 2009
40
Deletion of protein tyrosine phosphatase 1b improves peripheral insulin resistance and vascular function in obese, leptin-resistant mice via reduced oxidant tone. 61 54
19797171 2009
41
[Secondary dyslipidaemia after oral contraceptives]. 54 61
19947236 2009
42
Adiponectin is associated with cardiovascular disease in male renal transplant recipients: baseline results from the LANDMARK 2 study. 61 54
19821969 2009
43
Increase in gamma-glutamyltransferase level and development of established cardiovascular risk factors and diabetes in Japanese adults. 61 54
19419267 2009
44
ACP1 genotype, glutathione reductase activity, and riboflavin uptake affect cardiovascular risk in the obese. 61 54
19570551 2009
45
Forkhead box transcription factor O1 inhibits cholesterol 7alpha-hydroxylase in human hepatocytes and in high fat diet-fed mice. 61 54
19463968 2009
46
Functional variant disrupts insulin induction of USF1: mechanism for USF1-associated dyslipidemias. 54 61
20031629 2009
47
Splenomegaly with sea-blue histiocytosis, dyslipidemia, and nephropathy in a patient with lecithin-cholesterol acyltransferase deficiency: a clinicopathologic correlation. 54 61
19592052 2009
48
Hypertension in children (12-14 years)--a case-control study in Bursa, Turkey. 54 61
20112598 2009
49
Determination of the Apo E genotype using LightCycler Apo E mutation detection kit. 61 54
19891383 2009
50
Adipokines and etiopathology of metabolic disorders. 54 61
19750255 2009
Sources

Variations for Lipid Metabolism Disorder

About this section

ClinVar genetic disease variations for Lipid Metabolism Disorder:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 APOE NM_000041.4(APOE):c.461G>T (p.Arg154Leu)SNV Likely pathogenic 375636 rs200703101 19:45412014-45412014 19:44908757-44908757
Sources

Expression for Lipid Metabolism Disorder

About this section
Search GEO for disease gene expression data for Lipid Metabolism Disorder.
Sources

Pathways for Lipid Metabolism Disorder

About this section

Pathways related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Metabolism 65
Show member pathways
 13.98 PPARG PPARA LPL LPA LIPC INS
2
Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) 65
Show member pathways
 12.75 PPARG PPARA LPL LEP HMGCR FADS1
3
Metabolism of water-soluble vitamins and cofactors 65
Show member pathways
 12.56 LPL APOE APOC3 APOB APOA1
4
Lipoprotein metabolism 65
Show member pathways
 12.45 LPL LPA LIPC CETP APOE APOC3
5
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.4 PPARG LEP INS HMGCR ADIPOQ
6
Metabolism of fat-soluble vitamins 65
Show member pathways
 12.24 LPL APOE APOC3 APOB APOA1
7
Folate Metabolism 1
Show member pathways
 12.24 SERPINE1 INS CRP APOE APOB APOA1
9
Mesenchymal Stem Cells and Lineage-specific Markers 64
11.78 PPARG LPL LEP INS ADIPOQ
10
Binding and Uptake of Ligands by Scavenger Receptors 65
Show member pathways
 11.77 APOE APOB APOA1
11
Adipogenesis 1
11.68 SERPINE1 RETN PPARG PPARA LPL LEP
12
Sterol Regulatory Element-Binding Proteins (SREBP) signalling 1
11.64 PPARG LPL INS HMGCR
13
PPAR signaling pathway 36
11.59 PPARG PPARA LPL APOC3 APOA5 APOA1
14
Adipocytokine signaling pathway 36
11.58 PPARA LEP ADIPOQ
15
Statin Pathway 1
Show member pathways
 11.39 LPL LPA LIPC HMGCR CETP APOE
16
Differentiation of white and brown adipocyte 1
11.11 PPARG LEP ADIPOQ
17
PPAR Alpha Pathway 1
11.08 PPARA APOC3 APOA5 APOA1
18
Transcription factor regulation in adipogenesis 1
11.04 PPARG LEP ADIPOQ
Sources

GO Terms for Lipid Metabolism Disorder

About this section

Cellular components related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.2 SERPINE1 RETN LPL LPA LIPC LEP
2 extracellular space GO:0005615 10.1 SERPINE1 RETN LPL LIPC LEP INS
3 collagen-containing extracellular matrix GO:0062023 9.91 SERPINE1 APOE APOC3 APOA1 ADIPOQ
4 endoplasmic reticulum lumen GO:0005788 9.91 LIPC INS APOE APOB APOA5 APOA1
5 early endosome GO:0005769 9.88 APOE APOC3 APOB APOA5 APOA1
6 low-density lipoprotein particle GO:0034362 9.71 APOE APOB APOA5 APOA1
7 intermediate-density lipoprotein particle GO:0034363 9.67 APOE APOC3 APOB APOA1
8 endocytic vesicle lumen GO:0071682 9.63 APOE APOB APOA1
9 high-density lipoprotein particle GO:0034364 9.63 LIPC CETP APOE APOB APOA5 APOA1
10 spherical high-density lipoprotein particle GO:0034366 9.52 APOC3 APOA1
11 discoidal high-density lipoprotein particle GO:0034365 9.49 APOE APOA1
12 very-low-density lipoprotein particle GO:0034361 9.43 LPL APOE APOC3 APOB APOA5 APOA1
13 chylomicron GO:0042627 9.1 LPL APOE APOC3 APOB APOA5 APOA1

Biological processes related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 10.07 INS APOE APOB APOA5 APOA1
2 lipid transport GO:0006869 10.07 LPA CETP APOE APOC3 APOB APOA5
3 negative regulation of inflammatory response GO:0050728 10.05 PPARG PPARA APOE APOA1 ADIPOQ
4 regulation of lipid metabolic process GO:0019216 10.05 PPARG PPARA HMGCR FADS1 APOA5 APOA1
5 steroid metabolic process GO:0008202 10.04 HMGCR CETP APOE APOB APOA1
6 fatty acid metabolic process GO:0006631 10.02 PPARG PPARA LPL FADS1
7 response to nutrient GO:0007584 10.02 PPARG LEP HMGCR FADS1 APOA1 ADIPOQ
8 retinoid metabolic process GO:0001523 10 LPL APOE APOC3 APOB APOA1
9 cholesterol metabolic process GO:0008203 10 LIPC LEP HMGCR CETP APOE APOB
10 lipid catabolic process GO:0016042 9.99 LPL LIPC APOC3 APOB
11 glucose homeostasis GO:0042593 9.98 PPARG LEP INS ADIPOQ
12 response to insulin GO:0032868 9.97 RETN PPARA LEP FADS1
13 triglyceride metabolic process GO:0006641 9.97 LPL CETP APOE APOC3 APOA5
14 response to nutrient levels GO:0031667 9.96 PPARG PPARA LEP ADIPOQ
15 intermembrane lipid transfer GO:0120009 9.94 CETP APOE APOB APOA1
16 cellular response to insulin stimulus GO:0032869 9.93 PPARG LEP ADIPOQ
17 response to organic substance GO:0010033 9.93 PPARG FADS1 APOB
18 triglyceride catabolic process GO:0019433 9.93 LPL LIPC APOC3 APOB APOA5
19 circadian rhythm GO:0007623 9.92 SERPINE1 LEP ADIPOQ
20 fatty acid biosynthetic process GO:0006633 9.91 LPL LIPC FADS1
21 cholesterol transport GO:0030301 9.91 LIPC CETP APOB APOA1
22 cholesterol efflux GO:0033344 9.91 APOE APOC3 APOB APOA5 APOA1
23 glucose metabolic process GO:0006006 9.9 LEP INS ADIPOQ
24 positive regulation of lipid biosynthetic process GO:0046889 9.9 INS APOE APOA5 APOA1
25 phospholipid efflux GO:0033700 9.89 APOE APOC3 APOA5 APOA1
26 reverse cholesterol transport GO:0043691 9.89 LIPC CETP APOE APOC3 APOA1
27 lipid homeostasis GO:0055088 9.88 PPARG CETP APOE
28 negative regulation of MAP kinase activity GO:0043407 9.88 HMGCR APOE ADIPOQ
29 chylomicron assembly GO:0034378 9.88 APOE APOC3 APOB APOA1
30 high-density lipoprotein particle remodeling GO:0034375 9.88 LIPC CETP APOE APOC3 APOA1
31 cholesterol biosynthetic process GO:0006695 9.87 HMGCR APOA5 APOA1
32 chylomicron remnant clearance GO:0034382 9.86 LIPC APOE APOC3 APOB
33 cholesterol homeostasis GO:0042632 9.86 LPL LIPC CETP APOE APOC3 APOB
34 negative regulation of protein secretion GO:0050709 9.85 INS HMGCR APOE
35 positive regulation of cholesterol efflux GO:0010875 9.85 APOE APOA1 ADIPOQ
36 phosphatidylcholine metabolic process GO:0046470 9.84 CETP APOA5 APOA1
37 high-density lipoprotein particle assembly GO:0034380 9.83 APOE APOA5 APOA1
38 negative regulation of blood vessel diameter GO:0097756 9.83 INS HMGCR CRP
39 low-density lipoprotein particle remodeling GO:0034374 9.83 LPA LIPC CETP APOE APOB
40 positive regulation of cholesterol esterification GO:0010873 9.82 APOE APOA5 APOA1
41 regulation of Cdc42 protein signal transduction GO:0032489 9.81 APOE APOC3 APOA1
42 lipoprotein biosynthetic process GO:0042158 9.8 APOE APOB APOA1
43 positive regulation of fatty acid metabolic process GO:0045923 9.8 PPARG PPARA ADIPOQ
44 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.8 PPARG PPARA CRP CETP ADIPOQ
45 lipoprotein metabolic process GO:0042157 9.8 PPARA APOE APOC3 APOB APOA5 APOA1
46 regulation of intestinal cholesterol absorption GO:0030300 9.79 LEP APOA5 APOA1
47 chylomicron remodeling GO:0034371 9.77 LPL APOE APOC3 APOB APOA1
48 positive regulation of fatty acid biosynthetic process GO:0045723 9.75 APOA5 APOA1
49 negative regulation of blood coagulation GO:0030195 9.75 SERPINE1 APOE
50 positive regulation of lipid storage GO:0010884 9.75 LPL APOB

Molecular functions related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 10.15 PPARG INS HMGCR CRP APOE APOA1
2 signaling receptor binding GO:0005102 9.95 SERPINE1 LPL LEP APOE APOA1 ADIPOQ
3 hormone activity GO:0005179 9.83 RETN LEP INS ADIPOQ
4 lipid binding GO:0008289 9.8 PPARG PPARA CETP APOE APOC3 APOA5
5 phospholipid binding GO:0005543 9.77 APOE APOC3 APOB APOA5 APOA1
6 cholesterol binding GO:0015485 9.73 CETP APOC3 APOA5 APOA1
7 lipid transporter activity GO:0005319 9.71 APOE APOB APOA1
8 phosphatidylcholine binding GO:0031210 9.69 CETP APOA5 APOA1
9 apolipoprotein binding GO:0034185 9.63 LPL LPA LIPC
10 heparin binding GO:0008201 9.63 LPL LPA LIPC APOE APOB APOA5
11 phospholipase A1 activity GO:0008970 9.6 LPL LIPC
12 phosphatidylserine 1-acylhydrolase activity GO:0052739 9.59 LPL LIPC
13 1-acyl-2-lysophosphatidylserine acylhydrolase activity GO:0052740 9.58 LPL LIPC
14 lipase inhibitor activity GO:0055102 9.58 APOC3 APOA1
15 lipoprotein particle binding GO:0071813 9.58 LPL APOE APOA1